The Dermavant Sciences logo.

Featured Searches

VTAMA® (tapinarof) cream, 1%

In the News

Careers

Leadership Team

Most Searched Tags

Clinical Trials Field Medical Director Compliance Program Medical Affairs Culture

CONTACT US

For Medical Information, Adverse Event Reporting or Product Quality Complaints, please call:

1-8-DERMAVANT (1-833-762-8268)

Monday - Friday | 8 a.m. - 8 p.m. ET

Additional contacts:

Media Inquiries

media@dermavant.com

Business Development

bd@dermavant.com

Investor Inquiries

ir@dermavant.com

Continuing Medical Education Grants

grants@dermavant.com

Investigator Initiated Studies

iis@dermavant.com

    *Required field

    Adverse Event Category

    Patient Information

    Reporter Information


    Product Information

    Treatment Dates



      *Required field

        *Required field


          *Required field

          Complaint Information

          Product Information

          Month

          Year

          Please direct any mail to our Long Beach, CA headquarters address.

          Long Beach, CA

          3780 Kilroy Airport Way
          Suite 250
          Long Beach, CA 90806
          United States

          4:35 AM (PST)

          Raleigh/Durham, NC

          3300 Paramount Parkway
          Suite 150
          Morrisville, NC 27560
          United States

          7:35 AM (EST)

          Southlake, TX

          2102 E State Hwy 114
          Floor 2, Suite 217
          Southlake, TX 76092
          United States

          6:35 AM (CST)

          Basel, Switzerland

          Viaduktstrasse 8
          4051 Basel
          Switzerland

          2:35 PM (GMT+2)

          Download our corporate fact sheet

          Download
           

          You are now leaving Dermavant.com

          You are now leaving www.dermavant.com. Links to sites outside of Dermavant are provided as a resource to the viewer. Dermavant accepts no responsibility for the content of linked sites.

          You are now leaving Dermavant.com

          You are now leaving www.dermavant.com. Links to sites outside of Dermavant are provided as a resource to the viewer. Dermavant accepts no responsibility for the content of linked sites.

          You are now leaving Dermavant.com

          You are now leaving www.dermavant.com. Links to sites outside of Dermavant are provided as a resource to the viewer. Dermavant accepts no responsibility for the content of linked sites.

          Important Safety Information

          Indication: VTAMA® (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults. Adverse Events: The most common adverse reactions (incidence ≥ 1%) in subjects treated with VTAMA cream were folliculitis (red raised bumps around the hair pores), nasopharyngitis (pain or swelling in the nose and throat), contact dermatitis (skin rash or irritation, including itching and redness, peeling, burning, or stinging), headache, pruritus (itching), and influenza (flu).

          You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.